Sublobar resection for early-stage lung cancer

Hiroyuki Sakurai, Hisao Asamura

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Since the 1995 report of the prospective randomized trial of lobectomy versus sublobar resection for stage I non-small cell lung cancer (NSCLC) performed by the the Lung Cancer Study Group, lobectomy remains the standard of care for the surgical management of stage I NSCLC. Sublobar resection has been typically used for high-risk patients who are operative candidates but for whom a lobectomy is contraindicated. Recent advances in imaging and staging modalities and improved spatial resolution of computed tomography (CT) scan have refined the presentation and diagnosis of early-stage NSCLC. The detection of small tumors and ground-glass opacity (GGO) appearance associated with a favorable histology have led to the increased use of sublobar resection in many institutes to include good-risk patients. There is an increasing body of evidence that sublobar resection may achieve oncological outcomes similar to those with lobectomy in early-stage NSCLC, especially that 2 cm or less in size. However, whether or not sublobar resection constitutes adequate treatment for small-sized lung cancer or for the radiographic "early" lung cancer such as a GGO-dominant lesion is still being prospectively investigated. Sublobar resection will be expected to play an important role as a primary treatment option for patients with small stage IA NSCLC, based on an anatomical functional advantage over lobectomy as well as comparable prognostic outcomes between sublobsar resection and lobectomy.

Original languageEnglish
Pages (from-to)164-172
Number of pages9
JournalTranslational Lung Cancer Research
Volume3
Issue number3
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Glass
Standard of Care
Histology
Tomography
Therapeutics
Neoplasms

Keywords

  • Early-stage lung cancer
  • Non-small cell lung cancer (NSCLC)
  • Prognosis
  • Sublobar resection
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Sublobar resection for early-stage lung cancer. / Sakurai, Hiroyuki; Asamura, Hisao.

In: Translational Lung Cancer Research, Vol. 3, No. 3, 2014, p. 164-172.

Research output: Contribution to journalArticle

@article{0ef7a43bdc50411aabf1997073c7df72,
title = "Sublobar resection for early-stage lung cancer",
abstract = "Since the 1995 report of the prospective randomized trial of lobectomy versus sublobar resection for stage I non-small cell lung cancer (NSCLC) performed by the the Lung Cancer Study Group, lobectomy remains the standard of care for the surgical management of stage I NSCLC. Sublobar resection has been typically used for high-risk patients who are operative candidates but for whom a lobectomy is contraindicated. Recent advances in imaging and staging modalities and improved spatial resolution of computed tomography (CT) scan have refined the presentation and diagnosis of early-stage NSCLC. The detection of small tumors and ground-glass opacity (GGO) appearance associated with a favorable histology have led to the increased use of sublobar resection in many institutes to include good-risk patients. There is an increasing body of evidence that sublobar resection may achieve oncological outcomes similar to those with lobectomy in early-stage NSCLC, especially that 2 cm or less in size. However, whether or not sublobar resection constitutes adequate treatment for small-sized lung cancer or for the radiographic {"}early{"} lung cancer such as a GGO-dominant lesion is still being prospectively investigated. Sublobar resection will be expected to play an important role as a primary treatment option for patients with small stage IA NSCLC, based on an anatomical functional advantage over lobectomy as well as comparable prognostic outcomes between sublobsar resection and lobectomy.",
keywords = "Early-stage lung cancer, Non-small cell lung cancer (NSCLC), Prognosis, Sublobar resection, Surgery",
author = "Hiroyuki Sakurai and Hisao Asamura",
year = "2014",
doi = "10.3978/j.issn.2218-6751.2014.06.11",
language = "English",
volume = "3",
pages = "164--172",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "3",

}

TY - JOUR

T1 - Sublobar resection for early-stage lung cancer

AU - Sakurai, Hiroyuki

AU - Asamura, Hisao

PY - 2014

Y1 - 2014

N2 - Since the 1995 report of the prospective randomized trial of lobectomy versus sublobar resection for stage I non-small cell lung cancer (NSCLC) performed by the the Lung Cancer Study Group, lobectomy remains the standard of care for the surgical management of stage I NSCLC. Sublobar resection has been typically used for high-risk patients who are operative candidates but for whom a lobectomy is contraindicated. Recent advances in imaging and staging modalities and improved spatial resolution of computed tomography (CT) scan have refined the presentation and diagnosis of early-stage NSCLC. The detection of small tumors and ground-glass opacity (GGO) appearance associated with a favorable histology have led to the increased use of sublobar resection in many institutes to include good-risk patients. There is an increasing body of evidence that sublobar resection may achieve oncological outcomes similar to those with lobectomy in early-stage NSCLC, especially that 2 cm or less in size. However, whether or not sublobar resection constitutes adequate treatment for small-sized lung cancer or for the radiographic "early" lung cancer such as a GGO-dominant lesion is still being prospectively investigated. Sublobar resection will be expected to play an important role as a primary treatment option for patients with small stage IA NSCLC, based on an anatomical functional advantage over lobectomy as well as comparable prognostic outcomes between sublobsar resection and lobectomy.

AB - Since the 1995 report of the prospective randomized trial of lobectomy versus sublobar resection for stage I non-small cell lung cancer (NSCLC) performed by the the Lung Cancer Study Group, lobectomy remains the standard of care for the surgical management of stage I NSCLC. Sublobar resection has been typically used for high-risk patients who are operative candidates but for whom a lobectomy is contraindicated. Recent advances in imaging and staging modalities and improved spatial resolution of computed tomography (CT) scan have refined the presentation and diagnosis of early-stage NSCLC. The detection of small tumors and ground-glass opacity (GGO) appearance associated with a favorable histology have led to the increased use of sublobar resection in many institutes to include good-risk patients. There is an increasing body of evidence that sublobar resection may achieve oncological outcomes similar to those with lobectomy in early-stage NSCLC, especially that 2 cm or less in size. However, whether or not sublobar resection constitutes adequate treatment for small-sized lung cancer or for the radiographic "early" lung cancer such as a GGO-dominant lesion is still being prospectively investigated. Sublobar resection will be expected to play an important role as a primary treatment option for patients with small stage IA NSCLC, based on an anatomical functional advantage over lobectomy as well as comparable prognostic outcomes between sublobsar resection and lobectomy.

KW - Early-stage lung cancer

KW - Non-small cell lung cancer (NSCLC)

KW - Prognosis

KW - Sublobar resection

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84929514179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929514179&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-6751.2014.06.11

DO - 10.3978/j.issn.2218-6751.2014.06.11

M3 - Article

AN - SCOPUS:84929514179

VL - 3

SP - 164

EP - 172

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 3

ER -